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Abstract: A retrospective study was performed to evaluate the outcome of alendronate (ALN) 
  treatment for seven years in postmenopausal Japanese women with osteoporosis. Forty-seven 
  postmenopausal women with osteoporosis (mean age at baseline 65.7 years) treated with 
ALN for over seven years in our outpatient clinic were analyzed. Lumbar spine bone mineral 
density (BMD) was measured using dual energy X-ray absorptiometry, and urinary levels of 
cross-linked N-terminal telopeptides of type I collagen (NTX) and serum alkaline phosphatase 
(ALP) were monitored during the seven-year treatment period. Urinary NTX and serum ALP 
levels decreased (-48.2% at three months and -15.7% at seven years, respectively) and lumbar 
spine BMD increased (+12.8% at seven years) compared with baseline values. No serious 
adverse events were observed, including osteonecrosis of jaw, atypical femoral diaphysis 
fractures, or atrial fibrillation. To our knowledge, this is the first report of the outcome of ALN 
treatment for seven years in Japanese patients with osteoporosis. ALN successfully suppressed 
bone turnover and increased lumbar spine BMD from the baseline value over the course of the 
seven-year treatment period without causing any severe adverse events.
Keywords: alendronate, osteoporosis, long-term treatment, bone mineral density, bone 
  turnover
Background
Osteoporosis most commonly affects postmenopausal women, placing them at increased 
risk of fractures. Alendronate (ALN) is widely used for the treatment of postmenopausal 
osteoporosis. The Fracture Intervention Trial demonstrated the antifracture efficacy of 
ALN for vertebral, nonvertebral, hip, and wrist fractures in postmenopausal women 
with osteoporosis.1,2 A recent systematic review analyzing 11 randomized controlled 
trials including 12,068 women has confirmed both clinically important and statistically 
significant reductions in vertebral, nonvertebral, hip, and wrist fractures for secondary 
prevention of osteoporosis (gold standard evidence).3 ALN is regarded as a first-line 
drug for the treatment of osteoporosis in Japan.
The long-term efficacy of antifracture drugs needs to be established. Bone et al4 
reported their experience using ALN to treat postmenopausal Western women with 
osteoporosis for a period of 10 years. Ten years of ALN treatment produced an increase 
in bone mineral density (BMD) of 13.7% at the lumbar spine, 10.3% at the trochanter, 
5.4% at the femoral neck, and 6.7% at the total proximal femur, compared with baseline 
values. Safety data, including fractures and stature, did not suggest that prolonged 
treatment resulted in any loss of benefit. Thus, the therapeutic effects of ALN were 
sustained, and the drug was well tolerated over a 10-year period.Therapeutics and Clinical Risk Management 2010:6 202
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In Japan, results of randomized controlled trials testing 
the effects of short-term (1–3 years) ALN treatment on 
BMD, bone turnover, and fracture incidence have been 
reported in postmenopausal women with osteoporosis.5–8 
ALN reduces bone turnover, increases lumbar and hip 
BMD, and prevents vertebral fractures. Recently, we 
reported that ALN successfully reduced bone turnover 
and maintained metacarpal BMD for five years in older 
  postmenopausal Japanese women with osteoporosis 
or osteopenia and clinical risk factors for fractures.9 To our 
knowledge, however, the outcome of long-term (more than 
five years) ALN treatment has not been previously reported 
in Japanese patients. Therefore, a retrospective study was 
performed to evaluate the outcome of ALN treatment for 
seven years in postmenopausal Japanese women with 
osteoporosis. The primary endpoint was lumbar spine 
BMD, and the secondary endpoint was biochemical 
markers. Adverse events such as osteonecrosis of the jaw 
(ONJ), atypical femoral diaphysis fractures, and atrial 
fibrillation,10–12 as well as incident osteoporotic fractures 
were also assessed.
Subjects and methods
subjects
Forty-seven postmenopausal Japanese women (age range 
52–83 years, mean age 65.7 years at the beginning of 
  treatment) who had been treated with ALN for over seven 
years were recruited from the outpatient clinic at Keiyu 
Orthopaedic Hospital (Gunma, Japan) during the period 
between July 1 and December 30, 2009. Exclusion criteria 
were a history of reflux esophagitis, gastric or duodenal 
ulcer, gastrectomy, or bone diseases secondary to primary 
  hyperparathyroidism, hyperthyroidism, Cushing’s syndrome, 
multiple myeloma, rheumatoid arthritis, and osteogenesis 
imperfecta.
All the patients had been diagnosed as having 
  osteoporosis according to the Japanese diagnostic 
  criteria.13,14 Namely, patients with a BMD  70% of the 
young adult mean (YAM) or a BMD 70%–80% of the 
YAM along with a history of osteoporotic fractures were 
diagnosed as having osteoporosis. Preliminary screening 
included a medical history, physical examination, plain 
X-rays of the thoracic and lumbar spine, lumbar spine BMD 
measurement, and blood and urinary biochemical tests, 
including serum calcium, phosphorus, alkaline phosphatase 
(ALP) and urinary cross-linked N-terminal telopeptides of 
type I collagen (NTX). Lumbar spine BMD was used for 
the diagnosis of osteoporosis.
The patients had been treated with ALN (5 mg daily 
or 35 mg weekly) over seven years. The doses indicated 
in parentheses above are the doses used in Japan for the 
  treatment of postmenopausal women with osteoporosis and 
have been recognized as being safe and effective.7 Daily ALN 
was available throughout the study period, but weekly ALN 
only became available in October 2006. All the patients had 
been treated with daily ALN and then switched to weekly 
ALN just after October 2006. The effects of daily and 
weekly ALN on BMD and bone turnover markers, as well 
as incidence of side effects, were reported to be similar in 
postmenopausal Japanese women with osteoporosis.8 The 
subjects did not receive any elementary calcium or natural 
vitamin D supplementation.
Urinary levels of NTX were measured three months after 
the start of treatment, based on the results of our previous 
study.15 Serum levels of calcium, phosphorus, and ALP, 
and lumbar spine BMD were measured every year after 
the start of treatment. Serum bone-specific ALP levels were 
also measured at seven years after the start of treatment. 
The outcome of seven years of ALN treatment was evaluated. 
The present study was approved by the Ethics Committee of 
Keiyu Orthopaedic Hospital.
Assessment of vertebral fractures
Plain lateral X-ray films of the thoracic and lumbar spine 
were obtained at baseline to detect evidence of morphometric 
  vertebral fractures. According to the Japanese criteria, 
a vertebral fracture was defined according to the vertebral 
height on lateral X-ray films.13,14 Briefly, the vertebral height 
was measured at the anterior (A), central (C), and posterior (P) 
aspects of the vertebral body, and the presence of a vertebral 
fracture was confirmed when a reduction in vertebral height 
of more than 20% (A, C, and P) compared with the height 
of the adjacent vertebrae was observed, the C/A or C/P was 
less than 0.8, or the A/P was less than 0.5. The assessment for 
vertebral fractures was performed at the T4–L4 level.
serum ALP, calcium, phosphorus,  
bone-specific ALP, and urinary NTX
Serum calcium, phosphorus, and ALP levels were measured by 
standard laboratory techniques (normal range 8.4–10.2 mg/dL, 
2.5–4.5 mg/dL, and 135–310 IU/L, respectively). Serum 
bone-specific ALP levels were measured by enzyme 
  immunoassay (EIA, normal range for Japanese women 
7.9–29.0 U/L).16 Urinary NTX levels were measured by 
enzyme-linked immunosorbent assay (ELISA, normal range 
9.3–54.3 nM bone collagen equivalent [BCE ]/mM Cr).16Therapeutics and Clinical Risk Management 2010:6 203
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Measurement of lumbar spine BMD
BMD of the lumbar spine (L1–L4) in the anteroposterior (AP) 
view was measured using dual-energy X-ray absorptiometry 
(DXA) with Hologic QDR 1500W apparatus (Bedford, MA). 
The coefficient of variation (100 × standard deviation/mean) 
of five measurements, with repositioning within 72 hours 
each time, was less than 1.2% in three persons.
statistical analysis
Data were expressed as the mean ± standard deviation (SD) 
in the table and the mean ± 95% confidence interval (CI) for 
calcium, phosphorus, and ALP, and the median ± 95% CI for 
urinary NTX in the figures. The significance of longitudinal 
changes in the BMD and biochemical markers was determined 
using a one-way analysis of variance (ANOVA) with repeated 
measurements. All statistical analyses were performed using 
the Stat View-J5.0 program on a Windows computer. A signifi-
cance level of P  0.05 was used for all the comparisons.
Results
Characteristics of subjects  
at start of treatment
Table 1 shows the baseline characteristics of the study subjects 
at the start of ALN treatment. The mean age was 65.7 years. 
The mean lumbar spine BMD was 0.638 g/cm2 (62.7% of 
YAM). Twenty-three subjects (48.9%) had prevalent vertebral 
fractures, and the mean number of prevalent vertebral 
  fractures per subject was 2.5. The mean level of urinary 
NTX was 73.3 nmol BCE/mmol Cr, indicating high turnover 
osteoporosis (normal range 9.3–54.3 nM BCE/mM Cr).16
Changes in biochemical markers  
and lumbar spine BMD
Figure 1 shows the changes in the biochemical markers. 
  Urinary NTX levels decreased to the normal range 
(9.3–54.3 nmol BCE/mmol Cr)16 after three months of 
  treatment, and serum ALP levels decreased but remained 
within the normal range (135–310 IU/L) during the 
seven-year period. The mean change rate of the urinary NTX 
levels after three months of treatment was -48.2%. The mean 
change in serum ALP levels after two years of treatment 
was -24.1%, and this decrease continued gradually over 
the course of the seven-year treatment period (-23.9% at 
three years, -19.3% at five years and -15.7% at seven years). 
Serum calcium levels decreased after three years of treatment, 
and this effect was maintained. The mean change in serum 
calcium level after three months was -2.0%. However, the 
changes in the serum phosphorus levels were not significant 
during the course of the seven-year treatment period.
Figure 2 shows that the lumbar spine BMD continued 
to increase for seven years. Increase in lumbar BMD after 
three, five, and seven years of treatment was +6.1%, +9.4%, 
and +12.8%, respectively.
Adverse events
No serious adverse events, including ONJ, atypical femoral 
diaphysis fractures, or atrial fibrillation were observed.
Incident fractures
Osteoporotic fractures including vertebral, hip, wrist, and 
proximal humeral fractures were assessed. During the 
seven-year treatment period, two patients experienced 
  vertebral fractures and two patients experienced wrist 
  fractures. The incidence of osteoporotic fractures was 8.6% 
and that of vertebral fractures was 4.3%.
Discussion
To our knowledge, this is the first report showing the outcome 
of ALN treatment for seven years in Japanese patients with 
osteoporosis. ALN successfully suppressed bone turnover 
and increased lumbar spine BMD compared with baseline 
values over the seven-year treatment period without causing 
any severe adverse events in postmenopausal Japanese 
women with osteoporosis. Of importance is the effect of ALN 
treatment for seven years on lumbar spine BMD and bone 
turnover, the necessity of long-term ALN treatment, and the 
Table 1 Characteristics of study subjects
Mean ± SD Range
Age (years) 65.7 ± 8.6 52–83
height (m) 1.48 ± 0.07 1.35–1.62
Body weight (kg) 45.4 ± 6.6 32–59
Body mass index (kg/m2) 20.5 ± 1.1 15.6–25.9
Lumbar spine BMD (g/cm2) 0.638 ± 0.091 0.433–0.788
% YAM of lumbar spine BMD (%) 62.7 ± 9.0 42.6–77.4
serum calcium (mg/dL) 9.4 ± 0.4 8.6–0.3
serum phosphorus (mg/dL) 3.3 ± 0.5 2.3–4.3
serum ALP (IU/L) 235 ± 62 132–398
Urinary NTX (nmol BCE/mmol Cr) 73.3 ± 21.2 30.6–135.1
number (%) of women with  
prevalent vertebral fractures
23 (48.9)
number (%) of women with  
history of nonvertebral fractures
3 (6.4)
Abbreviations: sD, standard deviation; BMD, bone mineral density; YAM, young 
adult mean; ALP, alkaline phosphatase; NTX, cross linked N-terminal telopeptides of 
type I collagen; BCe, bone collagen equivalent; Cr, creatinine.Therapeutics and Clinical Risk Management 2010:6 204
Iwamoto et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
incidence of adverse events including ONJ, atypical femoral 
diaphysis fractures, and atrial fibrillation.
Studies have shown that ALN (5 mg daily or 35 mg weekly) 
decreases urinary NTX (-45% at three months) and serum 
ALP (about -20% at three years), and increases in lumbar 
BMD (+9.2% at three years) in postmenopausal Japanese 
women with osteoporosis.6,8 Our previous study showed that 
ALN treatment for five years sustained metacarpal BMD 
  following reductions in urinary levels of NTX (-43.6% at 
three months) and serum levels of ALP (-18.0% at five years). 
In the present study, ALN treatment increased lumbar spine 
BMD (6.1% at three years) subsequent to reductions in 
urinary levels of NTX (-48.2% at three months) and serum 
levels of ALP (-24.1% and -19.3% at three and five years, 
respectively). The results of the present study are comparable 
with those of previous studies.
Urinary NTX levels were reduced to within the normal 
range for Japanese women after three months of treatment, 
while serum ALP levels remained within the normal range 
throughout the seven-year treatment period. Measurement of 
urinary NTX levels was permitted only twice (just before and 
within six months after the start of medication) in Japan for 
medical insurance reason. Thus, we evaluated urinary NTX 
only at three months after the start of treatment, because a 
urinary NTX measurement performed at this time provides 
important information and is sufficient to monitor the effects 
of treatment for osteoporosis.15 We failed to show urinary 
NTX data after seven years of ALN treatment. However, we 
evaluated serum bone-specific ALP levels (normal range 
for Japanese women 7.9–29.0 U/L)16 after seven years of 
  treatment. Serum levels of bone-specific ALP (mean ± SD) at 
seven years was 10.0 ± 2.0 U/L, suggesting a sustained effect 
of ALN treatment on bone turnover for seven years.
How long postmenopausal women with osteoporosis can 
continue ALN treatment is debatable. A survey of the effects 
of treatment discontinuation would provide valuable infor-
mation on this issue. Several reports have demonstrated that 
discontinuation of ALN affects BMD and/or levels of bone 
resorption markers at 1–2 years of discontinuation after 
1–2 years of treatment, two years of discontinuation after 
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Figure 1 Changes in biochemical markers.
Data were expressed as the mean ± 95% confidence interval (CI) for calcium, phosphorus, and ALP and the median ± 95% CI for urinary NTX. One-way ANOVA with repeated 
measurements showed that changes in calcium and ALP, but not those in phosphorus, were significant (P  0.0001 and P = 0.0036,  respectively). Dashed lines are the upper 
(9.3 nM BCE/mM Cr) and lower (54.3 nM BCE/mM Cr) limits of urinary NTX levels. The normal range of serum ALP was 135–310 IU/L.
Abbreviations: ALP, alkaline phosphatase; NTX, cross-linked N-terminal telopeptides of type I collagen.Therapeutics and Clinical Risk Management 2010:6 205
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two years of treatment, and 3–7 years of discontinuation 
after 2–6 years of treatment all decreased the BMD toward 
the baseline level.17–19 Discontinuation of ALN treatment for 
five years after five years of treatment resulted in a gradual 
loss of its effects, as measured using BMD and biochemical 
markers of bone turnover,4 and increased the risk of clinical 
vertebral fractures, compared with continuation of ALN 
treatment.20 A recent study also showed that among women 
without any vertebral fractures after five years of ALN treat-
ment, continuation of ALN treatment for another five years 
reduced the risk of nonvertebral fractures in women with 
a femoral neck BMD T-score  -2.5 at five years, but not 
in women with a T-score  -2, compared with the discon-
tinuation of ALN treatment for five years after five years 
of treatment.21 These results suggest that continuous ALN 
treatment for 10 years is optimal for selected patients.
If patients are not considered to have a high risk of 
  fractures, the discontinuation of ALN treatment could 
probably be considered after treatment for five years, 
with subsequent monitoring of BMD and bone turnover 
markers. The most important risk factor for fractures is 
considered to be BMD.21 Other risk factors are low-trauma 
fractures after the age of 40 years, a maternal history of 
  osteoporotic fractures after the age of 65 years, a thin body 
build, prolonged amenorrhea, early menopause, chronic 
  corticosteroid use (six months), and diseases predisposing 
an individual to osteoporosis.22 In the present study, treatment 
was continued in all patients because they had BMD below 
70% of the YAM or at least one of the aforementioned risk 
factors, as evaluated at the lumbar spine after five years of 
ALN treatment.
ONJ, atypical femoral diaphysis fractures, and atrial 
fibrillation have been reported as severe adverse events,10–12 
although whether these events are significantly related to 
ALN treatment remains uncertain. The efficacy and safety 
of ALN for 10 years has been established in postmenopausal 
Western women with osteoporosis.4 However, adherence 
(persistence and compliance) of patients to treatment with 
oral bisphosphonates is very poor.23 Because patients who 
withdrew from treatment were not followed up, the long-term 
safety of ALN remains uncertain in this patient group.
Once-yearly intravenous zoledronate has been reported to 
prevent morphometric vertebral, nonvertebral, and hip frac-
tures in postmenopausal women with osteoporosis effectively 
(relative risk 0.30, 0.75, and 0.59, respectively)24 and reduce 
mortality in patients who suffer a low-trauma hip fracture.25 
Because adherence to treatment with once-yearly intravenous 
zoledronate may be better than that with oral alendronate in 
clinical practice, zoledronate could be more useful in the 
prevention of osteoporotic fractures and reduce medical 
expenses related to treatment of hip fractures.
The incidence of vertebral fractures was 4.3% in the 
  present study. A RCT of the two-year minodronate study 
showed that the incidence of vertebral and nonvertebral 
  fractures in postmenopausal Japanese controls with 
  established osteoporosis was 21.3% and 3.5%, respectively.26 
However, a three-year RCT of ALN showed that the incidence 
of vertebral fractures was 2% for the ALN group and 8% for 
the active control (alfacalcidol) group in postmenopausal 
  Japanese women with osteoporosis.6 One possible explanation 
for the higher incidence of vertebral fractures in the present 
study might be that there was a higher proportion of patients 
who had prevalent vertebral fractures in terms of higher risk 
of incident fractures at baseline as well as a comparatively 
long duration of observation. Another possibility might be 
the existence of subclinical osteomalacia on a background 
of significantly decreased serum calcium levels because of 
lack of calcium and vitamin D supplementation.
The present study confirmed the effect of ALN on lumbar 
spine BMD and bone turnover in postmenopausal Japanese 
women with osteoporosis who continued treatment for seven 
years. However, this study has notable limitations. First, it 
was a retrospective cohort study with a small sample size. 
Second, the subjects did not receive either elementary calcium 
or natural vitamin D supplementation. Natural vitamin D 
supplementation is not routinely given in Japan. This makes 
it difficult to compare our study with those of others, as most 
other studies have included postmenopausal women with 
osteoporosis taking calcium and vitamin D supplements. 
Moreover, performing a seven-year RCT with a sufficient 
number of subjects is difficult, but prospective studies with 
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Figure 2 Changes in lumbar spine BMD.
Data were expressed as the mean ± 95% confidence interval (CI). One-way ANOVA 
with repeated measurements showed that changes in lumbar spine BMD were 
significant (P  0.0001).
Abbreviation: BMD, bone mineral density.Therapeutics and Clinical Risk Management 2010:6
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a large number of subjects are needed to establish the long-
term efficacy and safety of ALN treatment with calcium and 
vitamin D supplementation.
In conclusion, the present retrospective study showed that 
ALN successfully suppressed bone turnover and increased 
lumbar spine BMD, compared with baseline values, over the 
course of a seven-year treatment period without causing any 
severe adverse events in postmenopausal Japanese women 
with osteoporosis.
Disclosures
The authors report no funding sources or conflict of interest 
in this work.
References
  1.  Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect 
of alendronate on risk of fracture in women with existing vertebral 
fractures. Lancet. 1996;348:1535–1541.
  2.  Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate 
on risk of fracture in women with low bone density but without 
  vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 
1998;280:2077–2082.
  3.  Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary 
and secondary prevention of osteoporotic fractures in postmenopausal 
women. Cochrane Database Syst Rev. 2008;23(1):CD001155.
  4.  Bone HG, Hosking D, Devogelaer JP, et al. Alendronate Phase III 
Osteoporosis Treatment Study Group. Ten years’ experience with 
alendronate for osteoporosis in postmenopausal women. N Engl J Med. 
2004;350:1189–1199.
  5.  Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate 
in reducing the risk for vertebral fracture in Japanese patients 
with osteoporosis: A randomized, double-blind, active-controlled, 
double-dummy trial. Curr Ther Res. 2002;63:9:606–620.
  6.  Kushida K, Shiraki M, Nakamura T, et al. Alendronate reduced vertebral 
fracture risk in postmenopausal Japanese women with osteoporosis: 
A 3-year follow-up study. J Bone Miner Metab. 2004;22:462–468.
  7.  Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter 
comparative study between alendronate and alfacalcidol in Japanese 
patients with osteoporosis. Osteoporos Int. 1999;10:183–192.
  8.  Uchida S, Taniguchi T, Shimizu T, et al. Therapeutic effects of 
  alendronate 35 mg once weekly and 5 mg once daily in Japanese 
patients with osteoporosis: A double-blind, randomized study. 
J Bone Miner Metab. 2005;23:382–388.
  9.  Iwamoto J, Miyata A, Sato Y, et al. Five-year alendronate treatment 
  outcome in older postmenopausal Japanese women with osteoporosis 
or osteopenia and clinical risk factors for fractures. Ther Clin Risk 
Manag. 2009;5:773–779.
10.  Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral 
and Maxillofacial Surgeons position paper on bisphosphonate-related 
osteonecrosis of the jaws – 2009. Update. J Oral Maxillofac Surg. 
2009;67:2–12.
11.  Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral 
diaphysis in postmenopausal women taking alendronate. N Engl J Med. 
2008;358:1304–1306.
12.  Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk 
of incident atrial fibrillation in women. Arch Intern Med. 2008;168: 
826–831.
13.  Orimo H, Sugioka Y, Fukunaga M, et al. Diagnostic criteria of primary 
osteoporosis. J Bone Miner Metab. 1998;16:139–150.
14.  Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary 
osteoporosis: Year 2000 revision. J Bone Miner Metab. 2001;19: 
331–337.
15.  Iwamoto J, Takeda T, Sato Y, et al. Early changes in urinary cross-linked 
N-terminal telopeptides of type I collagen level correlate with one-year 
response of lumbar bone mineral density to alendronate in Japanese 
postmenopausal women with osteoporosis. J Bone Miner Metab. 
2005;23:238–242.
16.  Nishizawa Y, Nakamura T, Ohta H, et al. Guidelines for the use 
of biochemical markers of bone turnover in osteoporosis (2004). 
J Bone Miner Metab. 2005;23:97–104.
17.  Ravn  P,  Bidstrup  M, Wasnich  RD,  et  al. Alendronate  and 
estrogen-progestin in the long-term prevention of bone loss: Four-year 
results from the early postmenopausal intervention cohort study. 
A randomized, controlled trial. Ann Intern Med. 1999;131:935–942.
18.  Stock JL, Bell NH, Chesnut CH III, et al. Increments in bone mineral 
density of the lumbar spine and hip and suppression of bone turnover 
are maintained after discontinuation of alendronate in postmenopausal 
women. Am J Med. 1997;103:291–297.
19.  Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual 
effect on bone mass in postmenopausal Danish women up to seven years 
after treatment withdrawal. Bone. 2003;33:301–307.
20.  Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing 
or stopping alendronate after 5 years of treatment: The Fracture 
  Intervention Trial Long-term Extension (FLEX): A randomized trial. 
JAMA. 2006;296:2927–2938.
21.  Schwartz AV, Bauer DC, Cauley A, et al. Efficacy of continued 
  alendronate for fractures in women without prevalent vertebral fracture: 
The FLEX trial (Abstr 1057). Presented at the 29th Annual Meeting of 
the American Society for Bone and Mineral Research. Honolulu, HI; 
September 16–20, 2007.
22.  Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management 
of osteoporosis in postmenopausal women: Clinical guidelines. 
  International Committee for Osteoporosis Clinical Guidelines. 
Clin Ther. 1999;21:1025–1044.
23.  Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral 
bisphosphonate treatment and its consequences: A review of the 
  evidence. Expert Opin Pharmacother. 2009;10:1–13.
24.  Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic 
acid for treatment of postmenopausal osteoporosis. N Engl J Med. 
2007;356:1809–1822.
25.  Eriksen EF, Lyles KW, Colón-Emeric CS, et al. Antifracture efficacy and 
reduction of mortality in relation to timing of the first dose of zoledronic 
acid after hip fracture. J Bone Miner Res. 2009;24:1308–1313.
26.  Matsumoto T, Hagino H, Shiraki M, et al. Effect of daily oral 
  minodronate on vertebral fractures in Japanese postmenopausal women 
with established osteoporosis: A randomized placebo-controlled 
double-blind study. Osteoporos Int. 2009;20:1429–1437.